# A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines

> **NCT05248867** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 638 (actual)

## Conditions studied

- Glabellar Lines

## Interventions

- **DRUG:** Placebo
- **DRUG:** AGN-151586

## Key facts

- **NCT ID:** NCT05248867
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-16
- **Primary completion:** 2023-03-17
- **Final completion:** 2023-03-17
- **Target enrollment:** 638 (ACTUAL)
- **Last updated:** 2024-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05248867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05248867, "A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05248867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*